Nicox projects global sales of NCX 470 of over $300 million

French ophthalmology biotech company Nicox (Euronext: COX) has provided details of a US market survey evaluating the commercial potential of its investigational drug NCX 470, a nitric oxide (NO)-donating bimatoprost aimed at treating angle ocular or ocular hypertension.

The primary market research in the USA assumed NCX 470 obtains US Food and Drug Administration (FDA) approval with the safety and efficacy profile seen in the Mont Blanc Phase III trial.

Taking into account expected genericization of the market, basing the undiscounted price on appropriate branded references, and applying appropriate discounts, the net annual sales potential in the USA alone was estimated at between $115 and $165 million by year eight.